{
    "organizations": [],
    "uuid": "9a21f0304592df23880090452561eb07a064184c",
    "author": "Imani Moise",
    "url": "https://www.wsj.com/articles/samsung-biogen-reach-deal-with-abbvie-to-sell-near-copy-of-humira-1522937627",
    "ord_in_thread": 0,
    "title": "Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Samsung Bioepis Co. said Thursday it has reached a settlement with AbbVie Inc. that will allow it to market a near-replica version of one of the worldâ€™s top-selling drugs Humira.\nUnder the terms of the agreement, AbbVie will grant Samsung and its partner Biogen Inc. a nonexclusive license that allows the companies to sell their biosimilar version of the rheumatoid-arthritis treatment under the name Imraldi. AbbVie will also collect royalties from the companies once the product is launched.\n...  ",
    "published": "2018-04-05T18:13:00.000+03:00",
    "crawled": "2018-04-05T19:52:42.070+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "samsung",
        "bioepis",
        "said",
        "thursday",
        "reached",
        "settlement",
        "abbvie",
        "allow",
        "market",
        "version",
        "one",
        "world",
        "drug",
        "humira",
        "term",
        "agreement",
        "abbvie",
        "grant",
        "samsung",
        "partner",
        "biogen",
        "nonexclusive",
        "license",
        "allows",
        "company",
        "sell",
        "biosimilar",
        "version",
        "treatment",
        "name",
        "imraldi",
        "abbvie",
        "also",
        "collect",
        "royalty",
        "company",
        "product",
        "launched"
    ]
}